The challenges of antipsychotic polypharmacy
- PMID: 39547247
- DOI: 10.1016/S2215-0366(24)00367-5
The challenges of antipsychotic polypharmacy
Conflict of interest statement
JT and HT have participated in research projects funded by grants from Janssen to their employing institution. JT has been a consultant or advisor to or has received honoraria from Healthcare Global Village, HLS Therapeutics, Janssen-Cilag, Lundbeck, Orion, Otsuka, Teva, and WebMD Global. HT reports personal fees from Gedeon Richter, Janssen, Lundbeck, and Otsuka.
Comment on
-
Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.Lancet Psychiatry. 2024 Dec;11(12):975-989. doi: 10.1016/S2215-0366(24)00314-6. Epub 2024 Nov 12. Lancet Psychiatry. 2024. PMID: 39547246
References
Publication types
LinkOut - more resources
Full Text Sources